Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Cancer Genetics' UroGenRA-Kidney Array

Premium

Cancer Genetics, a Rutherford, NJ-based provider of oncology-focused molecular testing services, recently introduced UroGenRA-Kidney, a microarray intended for kidney cancer diagnosis and subtyping.

According to the company, the test is being offered in compliance with the US Clinical Laboratory Improvement Amendment and the approval of the New York State Department of Health. CGI said that the test will be offered to clients as part of its Kidney Complete Program, a suite of tests for kidney cancer.

It claims that UroGenRA-Kidney can be used to subtype kidney cancer tissue samples among three malignant renal cell carcinoma subtypes – clear cell, papillary, and chromophobe, as well as a benign form of renal cancer, oncocytoma. The company additionally claims that the data generated by the array can be used to select the appropriate therapy based on the kidney cancer subtype.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.